Palbociclib Synthesis: Segmented Addition for Impurity Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing processes for the synthesis of palbociclib result in high impurity formation and reduced yield due to improper addition methods and reaction conditions, particularly when the Grignard reagent is added in one lot or compound II is added all at once, leading to increased formation of undesired compounds VII, VIII, and IX.
Innovation Solution
The process involves adding compound II in multiple portions and maintaining the reaction temperature below 40°C during the coupling step with a Grignard reagent, followed by specific solvent and base treatments to obtain crystalline Form G of N-BOC palbociclib, characterized by distinct XRPD peaks, thereby reducing impurity content and enhancing purity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If compound II is added in one lot and Grignard reagent is added in one lot, then the process is simple and fast, but impurity content increases and purity decreases
Solution Approach 1:
The patent applies segmentation by dividing compound II into multiple portions (at least two portions) for addition to the reaction system, while the Grignard reagent is added in one lot. This segmented addition of compound II prevents excessive local concentration that leads to impurity formation (compounds VII, VIII, and IX), thereby maintaining high purity (>99%) while preserving reaction efficiency.
2Productivity
If reaction temperature is increased to accelerate reaction, then productivity improves, but impurity formation increases
Solution Approach 1:
The patent applies parameter changes by precisely controlling the reaction temperature to remain below 40°C during the coupling reaction. This temperature control parameter optimization prevents the formation of undesired compounds VII, VIII, and IX that occur at higher temperatures, while still allowing the reaction to proceed at acceptable rates when combined with the segmented addition method.
3Reliability
If conventional synthesis methods are used, then the process is well-established, but yield is reduced due to impurity formation
Solution Approach 1:
The patent maintains process reliability by using well-established Grignard coupling chemistry while improving yield through segmented addition of compound II. This approach reduces impurity formation (compounds VII, VIII, and IX) that otherwise consume starting materials and reduce yield, enabling the process to achieve >99% purity and significantly improved yield compared to conventional methods where compound II is added in one lot.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process achieves palbociclib with purity greater than 99% and impurity levels below 1% w/w, ensuring high yield and quality of the final product.
Implementation Method 1
reacting 6-bromo-2-chloro-8-cyclopentyl-5-methylpyrido[2,3-d]pyrimidin-7(8H)-one, a compound of formula II (the 'compound II') with tert-butyl 4-(6-amino-3-pyridyl) piperazine-1-carboxylate, a compound of formula III (the 'compound III') in the presence of a Grignard reagent
Implementation Method 2
heating the solution of the step (i)
Implementation Method 3
cooling the solution of the step (ii) or the step (iii)
Implementation Method 4
isolating the crystalline Form G of N-BOC palbociclib obtained in the step (iv)
Data Source
AI summary
The present invention relates to an improved process for the preparation of palbociclib. The present invention also relates to a novel crystalline Form G of tert-butyl 4-(6-{[6-(1-butoxyethenyl)-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl]amino}pyridin-3-yl)piperazine-1-carboxylate (also known as N-BOC palbociclib), and a process for its preparation. The novel Form G of tert-butyl 4-(6-{[6-(1-butoxyethenyl)-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl]amino}pyridin-3-yl)piperazine-1-carboxylate (also known as N-BOC palbociclib) is substantially in accordance with FIG. 1.